The Food and Drug Administration and over-the-counter statins: an opportunity lost?
Pickering
Thomas G
TG
Behavioral Cardiovascular Health and Hypertension Program, Columbia Presbyterian Medical Center, 622 West 168th Street, New York, NY 10032, USA.
D000328:Adult; D000368:Aged; D002318:Cardiovascular Diseases / Q000517:prevention & control; D000075202:Contraindications; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D008077:Lipoproteins, LDL / Q000097:blood; D008148:Lovastatin / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D004366:Nonprescription Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D017035:Pravastatin / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D012646:Self Administration; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008077:Lipoproteins, LDL; D004366:Nonprescription Drugs; D008148:Lovastatin; D017035:Pravastatin